Live tape
Top 8, mentions 7d28,335NVDA17,030 mentions▲ +0.03MSFT1,928 mentions-0.02AMD1,908 mentions▲ +0.10GOOGL1,892 mentions▲ +0.04AAPL1,539 mentions▲ +0.05SPCX1,482 mentions▲ +0.07SPY1,358 mentions▲ +0.05NBIS1,198 mentions▲ +0.07

Equity · Healthcare

VCYT

NASDAQ

Veracyte (VCYT)

59.12 USD +0.19% vs prior close
Veracyte, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
4.8B USD
P/E (TTM)
38.4
Revenue, year to Dec 2025
517.1M USD
EPS, diluted, year to Dec 2025
0.82 USD
52-week range
23.01 USD – 60.51 USD
Avg volume
257.8K

as of Jul 17, 2026

Have Veracyte (VCYT) insiders bought or sold shares recently?

In the 90 days to 15 Nov 2026, Veracyte insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase.

Form 4, 90 days to 15 Nov 2026, newest reported trade 27 Oct 2026

0buys
10sells
$2.86Mnet sold
10other filings
Have Veracyte (VCYT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
27 Oct 2026EASTHAM KARINDirectorSell14,850743K USD
27 Oct 2026Holstein JensDirectorSell7,500375K USD
19 Oct 2026Bhanji MunaDirectorSell1,86481K USD
24 Sep 2026Holstein JensDirectorSell7,500353K USD
21 Sep 2026Leite JohnGlobal Chief Commercial OffSell4,015161K USD
14 Sep 2026Holstein JensDirectorSell5,000205K USD
04 Sep 2026Chambers RebeccaChief Financial OfficerSell3,652157K USD
04 Sep 2026Febbo Phillip G.Chief Scientific & Med OfficerSell13,110564K USD
04 Sep 2026McGuire AnnieEVP, General CounselSell3,254140K USD
01 Sep 2026Bhanji MunaDirectorSell1,86480K USD
Sold10 open-market sales62,609$2.86M
10 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Veracyte (VCYT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
28 Oct 2026Wygant JonathanVP, Chief Accounting OfficerTax withheld1,30666K USD
27 Oct 2026EASTHAM KARINDirectorOption exercise10,000270K USD
27 Oct 2026Holstein JensDirectorOption exercise7,500265K USD
24 Sep 2026Holstein JensDirectorOption exercise7,500265K USD
02 Sep 2026Chambers RebeccaChief Financial OfficerTax withheld3,603162K USD
02 Sep 2026Febbo Phillip G.Chief Scientific & Med OfficerTax withheld3,639163K USD
02 Sep 2026Leite JohnGlobal Chief Commercial OffTax withheld3,961178K USD
02 Sep 2026McGuire AnnieEVP, General CounselTax withheld3,215144K USD
02 Sep 2026Stapley MarcChief Executive OfficerTax withheld8,782394K USD
02 Sep 2026Wygant JonathanVP, Chief Accounting OfficerTax withheld1,36161K USD

Which funds hold Veracyte (VCYT)?

2 of the 45 institutional funds we track reported a Veracyte position for the quarter ended 30 Sep 2026 — a combined 167.9M USD; the latest of those filings landed 13 Nov 2026.

Form 13F

Which funds hold Veracyte (VCYT)?
FundPositionSharesValueShares q/q
ARK Investment ManagementAdded2,964,650136.5M USD+29.1%
Fisher Asset ManagementHeld (±25%)682,71131.4M USD−2.6%
Marshall WaceExited

Have members of Congress traded Veracyte (VCYT)?

The most recent congressional trade disclosed in Veracyte is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 12 Nov 2025.

STOCK Act disclosures

Have members of Congress traded Veracyte (VCYT)?
TradedMemberTypeAmountFiled after
12 Nov 2025Gilbert Ray Cisneros, Jr.house · Democrat–CASale1K USD–15K USD33 days
16 Jun 2025Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD24 days
16 Oct 2023Josh Gottheimerhouse · Democrat–NJPurchase1K USD–15K USD26 days
15 Sep 2023Josh Gottheimerhouse · Democrat–NJSale1K USD–15K USD30 days
10 Apr 2023Daniel S. Goldmanhouse · Democrat–NYSale1K USD–15K USD39 days
23 Dec 2020Gilbert Ray Cisneros, Jr.house · Democrat–CASale1K USD–15K USD19 days
08 Dec 2020Josh Gottheimerhouse · Democrat–NJSale1K USD–15K USD30 days
29 Oct 2020Gilbert Ray Cisneros, Jr.house · Democrat–CASale1K USD–15K USD7 days

What has been filed or recorded for Veracyte (VCYT)?

The filings we hold for Veracyte, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Veracyte (VCYT)?
And
09 Oct 2026Fails to deliverShares failed to deliver373 shares16K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver18,299 shares790K USD notional · 0.023% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.38 USD
30 Sep 2026FinancialsTotal assets1.6B USDat period end
30 Sep 2026FinancialsTotal equity1.4B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 0.31 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.35 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 0.82 USD
31 Dec 2025FinancialsRevenue517.1M USDfiscal year
31 Dec 2025FinancialsNet income66.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS0.82 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.24 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.01 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.09 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 0.31 USD

What do people ask about Veracyte (VCYT)?

From live data
What is Veracyte’s market cap?4.8B

Veracyte is worth 4.8B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Veracyte’s P/E ratio?38.4

Veracyte has a price-to-earnings ratio of 38.4, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Veracyte’s revenue?517.1M

Veracyte reported revenue of 517.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Veracyte insiders bought or sold shares recently?10 sales

In the 90 days to 15 Nov 2026, Veracyte insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase. A further 10 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Veracyte?2 of 45

2 of the 45 funds we track reported a Veracyte position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Fisher Asset Management and Marshall Wace. See Funds

Have members of Congress traded Veracyte?9 trades

Yes. 9 trades in Veracyte appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 12 Nov 2025, filed 15 Dec 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Veracyte last report earnings?0.38

Veracyte last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.38 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain; Daniel S. Goldman: US House, Public domain; Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings